Anti-CD38 Targeted Nanoparticles for Drug Delivery in Multiple Myeloma

被引：0
|
作者：
De La Puente, Pilar [1 ]
Jin, Abbey [1 ,2 ]
Luderer, Micah John [1 ]
Muz, Barbara [1 ]
King, Justin A. [3 ]
Vij, Ravi [3 ]
Azab, Abdel Kareem [1 ]
机构：
[1] Washington Univ St Louis, Sch Med, Div Canc Biol, Dept Radiat Oncol, St Louis, MO USA
[2] St Louis Coll Pharm, Dept Pharmaceut & Adm Sci, St Louis, MO USA
[3] Washington Univ, Sch Med, Div Oncol, Dept Med, St Louis, MO USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2135.2135
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2135
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma
    Shah, Bhavesh
    Gray, Joy
    Abraham, Ivo
    Chang, Melody
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 170 - 182
  • [22] EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
    Chemlal, Djamila
    Varlet, Emmanuel
    Machura, Amelie
    Ovejero, Sara
    Requirand, Guilhem
    Robert, Nicolas
    Cartron, Guillaume
    Alaterre, Elina
    Bret, Caroline
    Vincent, Laure
    Herbaux, Charles
    Cavalli, Giacomo
    Bruyer, Angelique
    De Boussac, Hugues
    Moreaux, Jerome
    LEUKEMIA, 2023, 37 (9) : 1925 - 1928
  • [23] Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
    Zannetti, Beatrice Anna
    Faini, Angelo Corso
    Massari, Evita
    Geuna, Massimo
    Maffini, Enrico
    Poletti, Giovanni
    Cerchione, Claudio
    Martinelli, Giovanni
    Malavasi, Fabio
    Lanza, Francesco
    CELLS, 2020, 9 (12) : 1 - 13
  • [24] SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA (MM) REFRACTORY TO PROTEASOME INHIBITORS, IMMUNOMODULATORS, AND ANTI-CD38
    Gener Ricos, G.
    Abril Sabater, L.
    Ibarra Fernandez, G.
    Franch Sarto, M.
    Santos Gomez, M.
    Canamero Giro, E.
    Comes Escoda, M.
    Espasa Perez, A.
    De La Fuente Montes, C.
    Huguet Mas, M.
    Quintela Vilchez, D.
    Ribera-Santasusana, J. M.
    Oriol Rocafiguera, A.
    HAEMATOLOGICA, 2019, 104 : 9 - 10
  • [25] Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab
    Thirkettle, Sally
    Russell, Joanne
    Wilson, Sarah
    Ganijee, Tasneem
    Kulkarni, Samar
    Cavet, Jim
    Monaghan, Phillip J.
    ANNALS OF CLINICAL BIOCHEMISTRY, 2020, 57 (02) : 178 - 181
  • [26] Clinical outcomes of Multiple Myeloma patients after anti-CD38 monoclonal antibodies failure
    Zamanillo, Irene
    De la Puerta, Rosalia
    Gil, Rodrigo
    Poza, Maria
    De la Puerta, Rodrigo
    Alonso, Rafael
    Cedena, Teresa
    Calbacho, Maria
    Ayala, Rosa
    Martinez-Lopez, Joaquin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S164 - S165
  • [27] Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma
    Rabut, Elodie
    Castro-Fernandez, Annabelle
    Le Gall, Virginie
    Meknache, Nihad
    ANNALES DE BIOLOGIE CLINIQUE, 2017, 75 (03) : 351 - 355
  • [28] Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
    Zamagni, Elena
    Tacchetti, Paola
    Pantani, Lucia
    Cavo, Michele
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (05) : 423 - 435
  • [29] Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38-Targeted Lipid Nanoparticles
    Tarab-Ravski, Dana
    Hazan-Halevy, Inbal
    Goldsmith, Meir
    Stotsky-Oterin, Lior
    Breier, Dor
    Naidu, Gonna Somu
    Aitha, Anjaiah
    Diesendruck, Yael
    Ng, Brandon D.
    Barsheshet, Hagit
    Berger, Tamar
    Vaxman, Iuliana
    Raanani, Pia
    Peer, Dan
    ADVANCED SCIENCE, 2023, 10 (21)
  • [30] Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects
    Horenstein, Alberto L.
    Faini, Angelo C.
    Morandi, Fabio
    Ortolan, Erika
    Storti, Paola
    Giuliani, Nicola
    Richardson, Paul G.
    Malavasi, Fabio
    FRONTIERS IN IMMUNOLOGY, 2025, 16
12345